Align Technology reported a strong finish to fiscal 2025 with Q4 revenue of $1.048 billion, up 5.3% year-over-year, and full-year revenue reaching a record $4.0 billion, up 1%. The company delivered record clear aligner volumes of 677,000 cases in Q4 (up 7.7% YoY) and achieved a non-GAAP operating margin of 26.1%, the highest since 2021. Growth was driven by double-digit volume increases in international markets (EMEA, APAC, LatAm) and robust performance from Dental Support Organizations (DSOs), which offset continued softness in North America retail. For 2026, management guides for 3-4% revenue growth and a 100 basis point expansion in non-GAAP operating margin to approximately 23.7%, despite anticipated headwinds from product mix and the ramp-up of direct fabrication technology.
| Metric | Value | Change |
|---|---|---|
| Q4 Total Revenue | $1.048 billion | +5.3% year-over-year |
| Full Year 2025 Revenue | $4.0 billion | +1% year-over-year |
| Q4 Clear Aligner Volume | 677,000 cases | +7.7% year-over-year |
| Q4 Non-GAAP Operating Margin | 26.1% | +300 basis points year-over-year |
| Q4 Non-GAAP EPS | $3.29 | +$0.85 year-over-year |
| 2026 Revenue Guidance | Up 3-4% | Year-over-year |
| 2026 Non-GAAP Operating Margin Guidance | Approximately 23.7% | +100 basis points year-over-year |
DSOs (Dental Service Organizations) have emerged as Align's most critical growth engine, with top 10 DSOs in The Americas growing double digits and some growing triple digits. Management emphasized that DSOs are 'ideal partners' because their scale and need for efficiency align perfectly with Align's digital ecosystem. This strategic pivot reduces reliance on the volatile independent retail market and leverages Align's ability to scale treatment planning and manufacturing for large networks, providing a more predictable revenue stream.
International markets are driving volume growth, offsetting North America stagnation. EMEA, APAC, and Latin America all delivered double-digit clear aligner volume growth in Q4. Align reached milestones of 1 million patients treated in Latin America, the UK, and Iberia. This geographic diversification is a key strategic pillar, allowing the company to tap into 'untapped demand' and less saturated markets while North America matures.
Align is aggressively pursuing the 'Teen and Growing Kids' demographic to secure future patient pipelines. Products like Invisalign First, the Palatal Expander, and MAOB are fueling this growth, with teen/kids starts up 7.8% for the full year. Management noted a 40% attachment rate where Palatal Expanders evolve into comprehensive Invisalign cases, demonstrating a successful product strategy to capture patients earlier in their treatment lifecycle.
The company is executing a major manufacturing transition to 'Direct Fabrication' (3D printing). While this technology promises design flexibility and long-term cost reduction, management acknowledged it will be 'margin dilutive' in 2026 until scale is achieved. This signals a strategic willingness to absorb short-term profit pressure to build a more advanced, cost-effective manufacturing infrastructure for the future.
Align is deepening its 'Digital Ecosystem' integration by combining iTero scanners, Exocad software, and AI-driven ClinCheck planning. The rollout of iTero Lumina (representing 86% of system units) and new software like Exocad ART aims to increase 'stickiness' by improving doctor workflow and patient conversion. This strategy positions Align not just as a product seller, but as an essential platform partner for dental practices.
North America Retail remains a significant weak point, with management admitting consumer sentiment and patient inflow are 'pressured.' While DSOs are growing, the independent retail channel—which constitutes a large portion of the business—showed only 'stability' rather than growth. Management explicitly stated they do not expect the economic situation in the US to improve in a way that drives volume, creating a ceiling on near-term growth potential.
Average Selling Price (ASP) is expected to decline by 1-2% in 2026. This pressure stems from a shift toward lower-priced international markets and the adoption of 'no-refinement' products. While volume may offset this, the structural decline in ASP highlights pricing power limitations and a shift toward a more value-oriented product mix to drive adoption.
The transition to Direct Fabrication (3D printing) presents a near-term financial risk. Management confirmed that this initiative will be margin dilutive in 2026 as they scale the technology. This headwind creates a tighter margin walk for the year, requiring flawless execution in other areas to meet the 100 basis point expansion target.
China's Volume Based Procurement (VBP) remains a looming uncertainty. While management notes that 85% of their China business is private and the public rollout is delayed, the implementation in public hospitals creates a 'fluid' environment. Any unexpected expansion of VBP into the private sector could disrupt growth in the APAC region.
The 2026 revenue guidance of 3-4% implies a significant deceleration from Q4's 5.3% growth rate. This conservative outlook suggests that management does not foresee a immediate catalyst for a demand surge and is heavily reliant on execution gains rather than market tailwinds to hit targets.
Overall: Management conveyed a tone of disciplined confidence and cautious optimism throughout the call. While celebrating the operational beat and international momentum, they remained grounded regarding the macroeconomic pressures facing North America retail, avoiding overly aggressive predictions for a consumer-led recovery. Their demeanor shifted from celebrating the 'stability' found in Q4 to a pragmatic focus on execution and 'active conversion' strategies during the Q&A.
Confidence: HIGH - Management provided specific quantitative drivers for their guidance, detailed the mechanics of their DSO growth, and articulated a clear path to margin expansion despite known headwinds like direct fabrication dilution and ASP pressure.
Management expects worldwide revenue growth of 3% to 4% year-over-year. This outlook assumes stable market conditions consistent with the second half of 2025 and excludes any significant impact from U.S. tariffs or China VBP implementation.
The company anticipates clear aligner volume growth in the mid-single digits year-over-year, driven by international expansion and DSO adoption.
Non-GAAP operating margin is expected to be approximately 23.7%, a 100 basis point improvement over 2025. GAAP operating margin is expected to be slightly below 18%, representing a 400 basis point improvement.
Revenue is projected to be between $1.01 billion and $1.03 billion, representing 3% to 5% year-over-year growth.
Management expects the average selling price (ASP) to be down 1% to 2% year-over-year due to geographic mix shifts and product mix changes (no-refinement options).
Hedging & Uncertainty: Management employed frequent hedging language regarding the macro environment and North America recovery. Terms like 'cautiously optimistic,' 'assuming no circumstances occur beyond our control,' and 'fluid' were used to describe the outlook. They notably avoided predicting a recovery in North America consumer demand, instead using the word 'stability' to describe the region, which implies a floor rather than growth. When discussing China VBP, they used 'implementation delays' and 'timing and scope remain fluid' to mitigate expectations. However, regarding operational execution and DSO growth, their language was more assertive, using phrases like 'grounded in the actions we're taking' and 'unmatched globally,' showing a clear distinction between what they can control (operations) and what they cannot (macro).
While the macro environment remains dynamic, we are cautiously optimistic. - Joe Hogan, President and CEO
I wouldn't call the economic situation in The United States better in any way in a sense of driving volume. - Joe Hogan, President and CEO
Expect ASPs to work... one to 2% down. - John Morici, CFO
Our confidence is grounded in the actions we're taking to actively manage the business. - John Morici, CFO
We're projecting... what we experienced in the second half of the year. - Joe Hogan, President and CEO
Timing and scope remain fluid. - Joe Hogan, President and CEO (on China VBP)
Analyst Sentiment: Analysts were generally constructive but probing, focusing heavily on the sustainability of DSO growth and the specific drivers behind the 'stability' in North America. There was skepticism regarding the conservative 3-4% revenue guidance for 2026 given the Q4 beat, with analysts like Elizabeth Anderson (Evercore) and Brandon Baskas (William Blair) asking if management was being too conservative or underestimating market recovery.
Management Responses: Management responses were direct and data-rich, particularly from CFO John Morici regarding margins and ASPs. Joe Hogan consistently steered questions about macro recovery back to company-specific 'active conversion' strategies. They were transparent about the 'softness' in North America retail but refused to rely on macroeconomic improvements for their targets, emphasizing execution instead.
North America Retail Stability: Analysts sought to clarify if the 'stability' in North America meant a return to growth or just a bottoming out. Management clarified it was a 'better platform' but not an economic recovery, driven by DSOs offsetting retail weakness.
DSO Growth Sustainability: Multiple questions focused on how much runway is left for DSO growth. Management indicated they are still early in the adoption curve with DSOs expanding globally and increasing their share of aligner cases.
ASP and Margin Drivers: Analysts drilled down on the mechanics of the 100 bps margin expansion and the 1-2% ASP decline. Management explained that while 'no-refinement' products lower ASP, they improve margins by reducing deferred revenue and manufacturing complexity.
China VBP Impact: Questions centered on the assumptions built into guidance regarding China's Volume Based Procurement. Management confirmed guidance assumes 'status quo' with no major disruption from VBP in 2026.
Align Technology remains the dominant player in digital orthodontics with a formidable competitive moat built on its integrated ecosystem of scanners, software, and clear aligners. The Q4 results demonstrated the company's ability to expand margins (26.1% non-GAAP) and grow volumes even in a challenging macro environment, highlighting operational resilience. The shift toward DSOs and international markets provides a strong hedge against North America retail saturation, and the 'Teen and Growing Kids' strategy offers a long-term growth runway. However, the investment thesis is tempered by the company's own conservative guidance for 2026 (3-4% revenue growth), which suggests that a significant demand rebound is not imminent. Headwinds from ASP pressure (down 1-2%) and the margin dilution from Direct Fabrication in 2026 create a tighter margin walk. While the company is executing well on what it can control, the stock appears to be in a 'show me' phase regarding North America consumer demand and the successful monetization of its heavy R&D investments. Investors should monitor North America patient inflow trends and the uptake of the new 3D printed products for signs of an inflection point.
The transcript reveals a broader trend of 'practice consolidation' in the dental industry, where independent retail practices are struggling with consumer sentiment and inflation, while large Dental Support Organizations (DSOs) are gaining market share. Management noted that DSOs are 'outpacing growth rates of traditional retail practices globally' and are becoming 'one of the most influential forces shaping digital dentistry.' This suggests a structural shift where scale and operational efficiency are becoming prerequisites for survival in the dental sector, potentially squeezing out smaller, independent practitioners who cannot afford the technology or marketing required to convert price-sensitive patients.